Acute Myeloid Leukemia: Incorporating the Latest Advances into Nursing Practice

Acute Myeloid Leukemia: Incorporating the Latest Advances into Nursing Practice

CNE
Sandra E. Kurtin, PhD, ANP-C, AOCN
Release Date: July 06, 2020

Expiration Date: July 06, 2021

Staying abreast of the most up-to-date approaches for the care of patients with acute myeloid leukemia (AML) can be very challenging. This activity is designed to assist the nursing care team in remaining up-to-date with advances in AML, including a number of new therapies that have been approved in the past couple years.

This activity was previously presented as a webinar with live Q&A in June of 2020. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene, a Bristol Myers Squibb Company, and Jazz Pharmaceuticals.

Begin

Managing AML at Every Stage

Managing AML at Every Stage

CNE
Pinkal Desai, MD, MPH, Alexander Perl, MD, Daniel A. Pollyea, MD, and Farhad Ravandi, MD
Release Date: April 26, 2019

Expiration Date: April 26, 2020

This activity will address several practice-related issues regarding the management of patients with acute myeloid leukemia. Nurses who provide direct patient care may encounter many different hematologic malignancies throughout their day. Consequently, they may face the challenge of remaining current on treatment and monitoring approaches for acute myeloid leukemia at all stages of the disease, from the newly diagnosed patient to the relapsed/refractory patient. Nurses must also understand key needs of younger and older patients. In this text-based activity, four expert faulty provide the background and insights needed to properly manage patients with AML.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals.
Begin